Why cure, why now?
Combination antiretroviral therapy (cART) is highly effective at preventing morbidity and mortality due to infection with human immunodeficiency virus (HIV), but does not eradicate the virus. Consequently, cART must be administered life-long. Recent progress has stimulated research towards a cure of HIV infection. Approaches under investigation include hematopoietic stem cell transplantation, latency reactivating agents, immune based therapies, and cell-based therapies. Each of these approaches carries potential risks that must be weighed against the availability of safe and effective cART. Balancing the risks and benefits of this research poses unique challenges to potential study participants, clinicians and investigators.
Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.|Harvard Medical School, Boston, Massachusetts, USA.
Daniel R
DR
Kuritzkes
D016915:AIDS Vaccines; D019380:Anti-HIV Agents / Q000627:therapeutic use; D035843:Biomedical Research / Q000941:ethics / Q000639:trends; D060740:Disease Eradication / Q000379:methods / Q000639:trends; D055808:Drug Discovery / Q000941:ethics; D015658:HIV Infections / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D018579:Patient Selection / Q000941:ethics*; D017735:Virus Latency / Q000187:drug effects
D016915:AIDS Vaccines; D019380:Anti-HIV Agents
Clinical trials; Ethics; HIV Infection and AIDS